Jazz Pharmaceuticals: Neoplasms trials
The registry lists 10 Neoplasms studies with Jazz Pharmaceuticals as lead sponsor. 0 are open to participants now and 4 have results posted.
Phase 1 5Phase 2 3Phase 3 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid TumorsTerminatedNCT05126433Phase 2Results posted
- A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced CancerCompletedNCT01424566Phase 3Results posted
- Sativex® for Relieving Persistent Pain in Patients With Advanced CancerCompletedNCT01361607Phase 3Results posted
- Sativex® for Relieving Persistent Pain in Participants With Advanced CancerCompletedNCT01262651Phase 3Results posted
- A JZP341 Study in Adult Participants With Advanced or Metastatic Solid TumorsTerminatedNCT05631327Phase 1
- A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal CancerCompletedNCT03929666Phase 2
- A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351CompletedNCT03555955Phase 1
- A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced CancerWithdrawnNCT02432612Phase 1
- A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent GlioblastomaCompletedNCT01812603Phase 1/2
- Phase I Study of mPEG-R-Crisantaspase Given IVCompletedNCT01551524Phase 1